Seattle-based biotech Immusoft has moved a step closer to beginning clinical trials on one of its gene therapies, following a $3m cash injection. The company said it had raised $32m, including from investors such as the Bill and Melinda Gates Foundation, which is backing research into treatments for cancer.
Seattle-based biotech Immusoft has moved a step closer to beginning clinical trials on one of its gene therapies, following a $3m cash injection. The company, which is using immune system programming to develop gene therapies for illnesses such as HIV, also unveiled Sean Ainsworth as its new CEO, with Immusoft founder Matthew Scholz moving to the position of CTO.